As the outcomes for applications of ABCB1 inhibitors in clinical settings have been disappointing, novel strategies to surmount ABCB1‐mediated cancer MDR, such as gene therapy approaches, are gaining more attention.18 The gene discussed is ABCB1; the disease is cancer.